相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study
Marie Jose Kersten et al.
HAEMATOLOGICA (2021)
Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma
Sherilyn A. Tuazon et al.
TRANSPLANTATION AND CELLULAR THERAPY (2021)
Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma
Pamela B. Allen et al.
BLOOD (2021)
90Y-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin's Lymphoma
Kevin C. Conlon et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2020)
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial
Paul J. Broeckelmann et al.
JAMA ONCOLOGY (2020)
ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma
Steven Park et al.
BLOOD ADVANCES (2020)
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation
Philippe Armand et al.
BLOOD (2019)
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study
Radhakrishnan Ramchandren et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma
Jeremy S. Abramson et al.
BLOOD (2019)
Phase I Study of a CD45-Targeted Antibody-Radionuclide Conjugate for High-Risk Lymphoma
Ryan D. Cassaday et al.
CLINICAL CANCER RESEARCH (2019)
Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)
R. Garcia-Sanz et al.
ANNALS OF ONCOLOGY (2019)
Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group
Alba M. Redondo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience
Chiara Ciochetto et al.
ANNALS OF HEMATOLOGY (2018)
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma
Yago Nieto et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
Ann S. LaCasce et al.
BLOOD (2018)
Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot study
Michael E. Autenrieth et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617:Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control
Clemens Kratochwil et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma
J. M. Connors et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse
Craig H. Moskowitz et al.
BLOOD (2018)
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
Alex F. Herrera et al.
BLOOD (2018)
Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
A. F. Herrera et al.
ANNALS OF ONCOLOGY (2018)
Early Treatment Intensification With R-ICE And 90Y-Ibritumomab Tiuxetan (Zevalin)-BEAM Stem Cell Transplantation In Patients With High Risk Diffuse Large B-Cell Lymphoma Patients And Positive Interim PET After 4 Cycles Of R-CHOP-14
Mark Hertzberg et al.
HAEMATOLOGICA (2017)
Intravesical radioimmunotherapy of carcinoma in situ of the urinary bladder after BCG failure
M. E. Autenrieth et al.
UROLOGE (2017)
Intravesical radioimmunotherapy of carcinoma in situ of the urinary bladder after BCG failure
M. E. Autenrieth et al.
UROLOGE (2017)
Early Treatment Intensification With R-ICE And 90Y-Ibritumomab Tiuxetan (Zevalin)-BEAM Stem Cell Transplantation In Patients With High Risk Diffuse Large B-Cell Lymphoma Patients And Positive Interim PET After 4 Cycles Of R-CHOP-14
Mark Hertzberg et al.
HAEMATOLOGICA (2017)
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding
Clemens Kratochwil et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party
L. Bento et al.
BONE MARROW TRANSPLANTATION (2017)
Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BCNU, Etoposide, Cytarabine, and Melphalan for Non-Hodgkin Lymphoma: The Role of Histology
Amrita Y. Krishnan et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
Anita Kumar et al.
BLOOD (2016)
Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma
Scott D. Ramsey et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma
Yago Nieto et al.
CANCER (2016)
Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study
Armando Santoro et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
Clemens Kratochwil et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment
Flora E. van Leeuwen et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 (225Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)
Joseph G. Jurcic et al.
BLOOD (2016)
Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas
Yago Nieto et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
Craig H. Moskowitz et al.
LANCET (2015)
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study
Alison J. Moskowitz et al.
LANCET ONCOLOGY (2015)
90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma
John E. Janik et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Autologous Transplantation for Transformed Non-Hodgkin Lymphoma Using an Yttrium-90 Ibritumomab Tiuxetan Conditioning Regimen
Matthew Mei et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma
Arne Kolstad et al.
BLOOD (2014)
Pharmacokinetics and Imaging of 212Pb-TCMC-Trastuzumab After Intraperitoneal Administration in Ovarian Cancer Patients
Ruby F. Meredith et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2014)
213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience
C. Kratochwil et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial
Javier Briones et al.
HAEMATOLOGICA (2014)
Dose Escalation and Dosimetry of First-in-Human α Radioimmunotherapy with 212Pb-TCMC-Trastuzumab
Ruby Meredith et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Phase II Trial of 131-Iodine Tositumomab with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B Cell Lymphoma
Julie M. Vose et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Phase III Randomized Study of Rituximab/Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma: Results From the BMT CTN 0401 Trial
Julie M. Vose et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma
Craig H. Moskowitz et al.
BLOOD (2012)
A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma
Avichai Shimoni et al.
CANCER (2012)
Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma
Barry J. Allen et al.
IMMUNOTHERAPY (2011)
Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma
Sally Arai et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia
Todd L. Rosenblat et al.
CLINICAL CANCER RESEARCH (2010)
Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial
D. Cordier et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma
Gairin Dancey et al.
CLINICAL CANCER RESEARCH (2009)
Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Jane N. Winter et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Shortening the timeline of pediatric phase I trials: The rolling six design
Jeffrey M. Skolnik et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Clinical experience with alpha-particle-emitting At-211: Treatment of recurrent brain tumor patients with At-211-labeled chimeric antitenascin monoclonal antibody 81C6
Michael R. Zalutsky et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
Interim analysis of oxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma
Chand Raja et al.
CANCER BIOLOGY & THERAPY (2007)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Dosimetry in myeloablative 90Y-labeled ibritumomab tiuxetan therapy:: Possibility of increasing administered activity on the base of biological effective dose evaluation.: Preliminary results
Carlo Chiesa et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2007)
Ifosfamide, gemcitabine, and vinorelbine: a now induction regimen for refractory and relapsed Hodgkin's lymphoma
Armando Santoro et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2007)
The anti-CD25 monoclonal antibody 7G7/B6, armed with the α-emitter 211At, provides effective radioimmunotherapy for a murine model of leukemia
Meili Zhang et al.
CANCER RESEARCH (2006)
Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance P
Stefan Kneifel et al.
CLINICAL CANCER RESEARCH (2006)
Intralesional targeted alpha therapy for metastatic melanoma
BJ Allen et al.
CANCER BIOLOGY & THERAPY (2005)
Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma
JM Vose et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Targeted at particle immunotherapy for myeloid leukemia
JG Jurcic et al.
BLOOD (2002)
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease:: a randomised trial
N Schmitz et al.
LANCET (2002)
Tumor therapy with targeted atomic nanogenerators
MR McDevitt et al.
SCIENCE (2001)
分享论文
